Patent application number | Description | Published |
20110182907 | Anti-alpha-Enolase I Antibodies for Diagnosis and Treatment of alpha-Enolase I-Associated Diseases - The invention relates to antibodies against α-enolase I, their pharmaceutical compositions and diagnosis and treatment uses. Particularly, the invention provides polyclonal anti-α-enolase I antibodies and monoclonal single-chain variable fragment (scFv) anti-α-enolase antibodies, pharmaceutical compositions containing the same and their uses in uses in diagnosis and treatment of cancers, autoimmune disorders, ischemia and bacterial infection. | 07-28-2011 |
20120207817 | SMALL INTERFERING RNAS AND METHODS FOR PREVENTION, INHIBITION AND/OR TREATMENT OF MALIGNANT PROGRESSION OF BREAST CANCER - The invention found that overexpression and activation of α9-nAChR are associated with tumorigenesis of breast cancer and create a number of small interfering RNAs to inhibit the expression of α9-nAChR so as to inhibit breast cancer. Therefore, the invention provides small interfering RNAs (siRNAs) for inhibiting expression of α9-nAChR so as to inhibit breast cancer, methods to prevent/inhibit/treat malignant progression of nicotine-derived-compound-induced breast cancer and method of determining malignant level of such breast cancer. | 08-16-2012 |
20120208872 | USE OF TEA POLYPHENOLS FOR TREATING AND/OR PREVENTING NICOTINE OR NICOTINE-DERIVED COMPOUNDS OR ESTROGEN INDUCED BREAST CANCER - This invention relates to methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer. | 08-16-2012 |
20120208873 | TEA POLYPHENOLS PRODUCTS FOR CEASING SMOKING AND TREATING AND/OR PREVENTING NICOTINE OR NICOTINE-DERIVED COMPOUNDS OR ESTROGEN INDUCED BREAST CANCER - This invention relates to methods of aiding smoking cessation and/or treating and/or preventing smoking addition or methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in aiding smoking cessation and/or treating and/or preventing smoking addition or treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer. | 08-16-2012 |
20120270799 | METHOD OF IDENTIFYING A CANDIDATE COMPOUND WHICH MAY INHIBIT a9-nAchR OVEREXPRESSION OR ESTROGEN RECEPTOR-DEPENDENT TRANSCRIPTION IN NICOTINE-DERIVED-COMPOUND-INDUCED BREAST CANCER CELLS - The invention relates to methods of identifying a candidate compound which may inhibit estrogen receptor-dependent transcription or α9-nAChR overexpression and proliferation of nicotine-derived-compound-induced breast cancer cells by using an activating protein 1 (AP1) polypeptide. The invention found that α9-nAChR has an activating protein 1 (AP1)-binding site, that the α9-nAChR promoter is located at the AP1-binding site, and that ERs specifically bind to the α9-nAChR promoter at the AP1-binding site, indicating that ER-induced α9-nAChR up-regulation plays a central role in the response to endogenous (E2) or exogenous (nicotine) stimulation. | 10-25-2012 |